Medical Affairs

Resources

Confronting unmet medical needs in patients with hematologic cancers and solid tumors

Despite best efforts, there are still cancers that recur or that are refractory; that cause heavily treated patients to fail multiple lines of therapy; and that do not produce a durable and complete response. Following are the diseases that need new approaches to address unmet medical needs in cancer therapy.

ACCESS MORE RESOURCES AT
ADCTMEDICAL.COM

EXPLORE OUR VIRTUAL
CONGRESS EXPERIENCE

Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL is an aggressive type of non-Hodgkin lymphoma that is curable with immunochemotherapy in 50% to 60% of cases.1 For the 40% of patients who fail 1L therapy, however, prognoses are poor, worsening with each line of therapy as the burden increases and chance for cure or long-term disease-free survival decreases.2,3

Hodgkin Lymphoma (HL)

Approximately 15% to 25% of the 16,500 patients diagnosed with HL each year in the U.S. and Europe have relapsed or refractory HL.4 While advances have been made in the treatment of HL, a significant unmet medical need remains in the relapsed or refractory HL patient population, especially those who have progressed following treatment with other novel agents.2

B-Cell Acute Lymphoblastic Leukemia (B-Cell ALL)

Adult patients with relapsed or refractory B-cell ALL have limited therapeutic options and prognosis is typically poor.5

Acute Myeloid Leukemia (AML)

AML is the most common leukemia in the US adult population. Patients expressing CD25 on their leukemia cells have a particularly poor prognosis.6

Selected Advanced Solid Tumors

There is an unmet medical need for patients with selected solid tumors that are locally advanced or metastatic and have failed or are intolerant to any established therapy.7

References: 1. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604-616. 2. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620 3. Klink AJ, Nabhan C, Lee CH, et al. J Clin Pathways. 2020;6:44-53. 4. ADC Therapeutics doses first patients in pivotal phase 2 clinical trial of ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma. News release. BioSpace; October 17, 2019. Accessed March 9, 2021. https://www.biospace.com/article/adc-therapeutics-doses-first-patients-in-pivotal-phase-2-clinical-trial-of-adct-301-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma/ 5. Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. Treatment of relapsed/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019;17(3):166-175. 6. Allan JN, Roboz GJ, Askin G, Ritchie E, Scandura J, Christos P, et al. Leuk Lymphoma. 2018;59(4):821-828. doi:10.1080/10428194.2017.1352089 7. Ascierto PA, Butterfield LH, Campbell K, et al. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy). J Transl Med. 2021;19(1):13. doi:10.1186/s12967-020-02627-y